首页> 外文期刊>BMC Complementary and Alternative Medicine >Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta-analysis
【24h】

Efficacy and safety of Tripterygium wilfordii hook F for chronic urticaria: a systematic review and meta-analysis

机译:雷公藤多用钩F治疗慢性荨麻疹的疗效和安全性:系统评价和荟萃分析

获取原文
           

摘要

The first-line agents comprising antihistamines for chronic urticaria, are not completely satisfactory. Tripterygium wilfordii Hook F (TwHF), a Chinese herb, has been developed into several Tripterygium agents and have definite effects on autoimmune and inflammatory diseases. In chronic urticaria, however, their values of practical application remain unclear. The aim of this study was to investigate the efficacy and safety of TwHF in patients with chronic urticaria. Several databases were systematically searched including PubMed, Embase, Cochrane Central Register of Controlled Trials, China Network Knowledge Infrastructure, Chinese Scientific Journals Database, Wan Fang Database, and Chinese Biomedicine. Randomized controlled trials comparing antihistamines with TwHF or Tripterygium agents in combination with antihistamines were included. Revman5.3 was utilized to calculate risk ratios (RR) with 95% confidence intervals (CI). This study was registered with PROSPERO, number CRD42018091595. Twenty-one trials with 2565 participants were included in this analysis. Meta-analysis showed that, when antihistamines were combined with TwHF and Tripterygium agents, the curative effect in cases of chronic urticaria was superior to that of antihistamines alone (RR: 1.40; 95% CI: 1.33–1.46). The incidence rates of gastrointestinal disorder (RR: 2.91; 95% CI: 1.70–4.99) and menstrual disorder (RR: 6.00; 95% CI: 1.79–20.13) in drug combination groups were higher than those in controls, while other adverse events were similar between the two groups. After treatment, Dermatology Life Quality Index (RR: 1.23; 95% CI: 1.09–1.40), quality of sleep (RR: 1.50; 95% CI: 1.07–2.12), and daily activity (RR: 1.49; 95% CI: 1.25–1.78) were all improved. Furthermore, drug combination groups demonstrated less relapse (RR: 0.34; 95% CI: 0.25–0.45). TwHF and Tripterygium agents, in combination with antihistamines, appear to be more effective than antihistamines alone. Nevertheless, adverse events cannot be ignored. Large sample, multi-center, high-quality clinical studies are needed to verify the exact effects and safety of TwHF and Tripterygium agents in treatment of chronic urticaria.
机译:包含用于慢性荨麻疹的抗组胺药的一线药物并不完全令人满意。雷公藤雷公藤(TwHF)是一种中草药,已发展成为多种雷公藤制剂,对自身免疫和炎性疾病具有明确的作用。然而,在慢性荨麻疹中,其实际应用价值仍不清楚。这项研究的目的是调查TwHF在慢性荨麻疹患者中的疗效和安全性。系统搜索了几个数据库,包括PubMed,Embase,Cochrane对照试验中央注册系统,中国网络知识基础设施,中国科学期刊数据库,万芳数据库和中国生物医学。包括比较抗组胺药与TwHF或雷公藤药与抗组胺药合用的随机对照试验。 Revman5.3用于计算具有95%置信区间(CI)的风险比(RR)。该研究已在PROSPERO注册,编号为CRD42018091595。本分析包括21565名参与者的试验。荟萃分析显示,将抗组胺药与TwHF和雷公藤药合用时,对慢性荨麻疹的疗效要优于单独使用抗组胺药(RR:1.40; 95%CI:1.33-1.46)。药物联合组胃肠道疾病(RR:2.91; 95%CI:1.70–4.99)和月经紊乱(RR:6.00; 95%CI:1.79-20.13)的发生率均高于对照组,而其他不良事件两组之间相似。治疗后,皮肤病生活质量指数(RR:1.23; 95%CI:1.09-1.40),睡眠质量(RR:1.50; 95%CI:1.07-2.12)和日常活动(RR:1.49; 95%CI: 1.25–1.78)均得到改善。此外,药物组合组的复发率较低(RR:0.34; 95%CI:0.25–0.45)。 TwHF和雷公藤药与抗组胺药合用似乎比单独使用抗组胺药更有效。然而,不良事件不容忽视。需要大样本,多中心,高质量的临床研究,以验证TwHF和雷公藤药治疗慢性荨麻疹的确切疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号